UCB's Global Corporate Website

Tackling epilepsy to deliver value to patients

Posted by
Allyson Funk, US Communications & Public Relations
16-Jun-2017
Brain diseases affect 1 in 6 people around the world. The range of conditions – and the impact on patients – affecting the central nervous system is wide and unlocking the science behind them is hard.

At UCB, we are committed to delivering value to patients and looking for new ways to help patients living with neurological diseases. One area where UCB has been working for decades is in epilepsy. While it is the most common serious neurological condition – defined by recurrent seizures – it manifests itself in different ways for different patients. To date, more than 100 different epilepsy syndromes have been identified.

MRI















For patients, seizure types and frequency vary greatly. Some are short, like muscle jerks, while others are prolonged convulsions. Some patients may experience them rarely, while others battle seizures multiple times per day. Focal seizures start in just one part of the brain, while generalized seizures are the result of simultaneous abnormal activity of the whole brain. For patients battling epilepsy, regaining control – and getting seizures under control – is often a primary goal.

We have come a long way in treatment. Today, nearly half of patients newly diagnosed with epilepsy become seizure free with their first anti-epileptic drug. But for 1 in 3 patients, seizures remain uncontrolled because no available treatment works for them. These are the great challenges we continue to tackle. Breakthrough science and technology can help unlock better ways to care for and treat patients living with epilepsy. Whether it is helping find a therapy that works for an individual patient faster or finding new ways to treat the root cause of disease, we are committed to continuing to unlock the science and find new ways to improve the lives of patients.

For more information on epilepsy visit EpilepsyAdvocate.com.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.

CAPTCHA

Enter the characters shown in the image.